Proteomics of Alzheimer's disease: Unveiling protein dysregulation in complex neuronal systems.
Alzheimer's disease (AD) and its progressive dementia is multifactorial, develops relatively sporadically, and involves multiple pathologies in the complex biological system of the brain. For these reasons, genetics alone is not likely to explain the molecular basis of this disease. Proteomics is contributing valuable information about the underlying molecular defects involved in AD development and progression, which includes oxidative damage to specific proteins, altered levels of synaptic components, and protein compositions of Aβ plaques and neurofibrillary tangles (pathological hallmarks of AD). However, emerging strategies in the field of proteomics which include more specific targeting of disease-related anatomical regions, targeting of specific subcellular compartments of functional relevance, novel approaches for large scale identification of regulatory post-translational modifications such as phosphorylation and O-GlcNAc, improved chromatographic separations of peptides for more comprehensive analysis of samples, and high-throughput quantitative strategies directly coupled with MS should greatly enhance the future of AD proteomics. The characterization of AD-specific alterations in proteomes should provide further insight into mechanisms of disease development and progression, provide biomarkers predicting disease development, and provide novel targets for therapeutic intervention.